November 2025 in “Journal of Investigative Dermatology” TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.
2 citations
,
November 2019 in “International Journal of Dermatology and Venereology” Chronic autoimmune urticaria can be managed with specific therapies and requires improved diagnosis and treatment methods.
45 citations
,
May 2024 in “International Journal of Molecular Sciences” Alopecia areata is caused by immune attacks on hair follicles, affecting hair growth and quality of life.
December 2025 in “Cosmetics” New treatments for alopecia show promise in restoring hair growth by targeting immune and hormonal factors.
Certain Chinese herbs may help treat kidney fibrosis by targeting TGF-β.
16 citations
,
July 2020 in “International Journal of Molecular Sciences” Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.
April 2016 in “Journal of Investigative Dermatology” Blocking Oncostatin M's role in the JAK-STAT pathway can stimulate hair growth in mice.
2 citations
,
April 2018 in “Journal of Investigative Dermatology” Frontal fibrosing alopecia shows increased inflammation and JAK-STAT pathway activity without reduced hair proteins.
11 citations
,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
Baricitinib may effectively treat oral lichen planus.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
2 citations
,
March 2024 in “Meditsinskiy sovet = Medical Council” JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
20 citations
,
January 2018 in “Expert opinion on emerging drugs” JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
9 citations
,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
4 citations
,
June 2023 in “Frontiers in immunology” JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
3 citations
,
June 2025 in “Archives of Dermatological Research” Biologics and JAK inhibitors may improve treatment for scarring alopecias.
1 citations
,
December 2022 in “The Nishinihon Journal of Dermatology” Baricitinib is an effective treatment for severe alopecia areata.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
11 citations
,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
November 2020 in “Journal of The American Academy of Dermatology” Oral JAK inhibitors help regrow hair in alopecia patients.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
3 citations
,
August 2025 in “Frontiers in Pharmacology” Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
November 2017 in “Asian journal of pharmaceutical and clinical research” Three compounds from Dadap leaves may help treat hair loss.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.